Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanisms of action of CHF3381 in the forebrain.
Barbieri M, Bregola G, Buzzi A, Marino S, Zucchini S, Stables JP, Bergamaschi M, Pietra C, Villetti G, Simonato M. Barbieri M, et al. Among authors: bergamaschi m. Br J Pharmacol. 2003 Aug;139(7):1333-41. doi: 10.1038/sj.bjp.0705381. Br J Pharmacol. 2003. PMID: 12890713 Free PMC article.
Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain.
Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, Rondelli I, Chamiot-Clerc P, Simonato M, Barbieri M. Villetti G, et al. Among authors: bergamaschi m. J Pharmacol Exp Ther. 2003 Aug;306(2):804-14. doi: 10.1124/jpet.103.050039. Epub 2003 May 15. J Pharmacol Exp Ther. 2003. PMID: 12750440
Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
Villetti G, Bregola G, Bassani F, Bergamaschi M, Rondelli I, Pietra C, Simonato M. Villetti G, et al. Among authors: bergamaschi m. Neuropharmacology. 2001 Jun;40(7):866-78. doi: 10.1016/s0028-3908(01)00026-0. Neuropharmacology. 2001. PMID: 11378157
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
Villetti G, Carnini C, Battipaglia L, Preynat L, Bolzoni PT, Bassani F, Caruso P, Bergamaschi M, Pisano AR, Puviani V, Stellari FF, Cenacchi V, Volta R, Bertacche V, Mileo V, Bagnacani V, Moretti E, Puccini P, Catinella S, Facchinetti F, Sala A, Civelli M. Villetti G, et al. Among authors: bergamaschi m. J Pharmacol Exp Ther. 2015 Mar;352(3):568-78. doi: 10.1124/jpet.114.220558. Epub 2015 Jan 9. J Pharmacol Exp Ther. 2015. PMID: 25576073
171 results